Dendritic cell co-stimulatory receptors

Dendritic cell (DC) co-stimulatory receptors are a heterogeneous group of cell-surface proteins that provide the secondary signals necessary for the activation, survival, and differentiation of T-cells during antigen presentation, often referred to as Signal 2. Key members include the B7 family proteins, such as CD80 and CD86, which bind to CD28 or CTLA-4 on T-cells, and members of the tumor necrosis factor receptor (TNFR) superfamily, such as CD40, OX40L (CD252), and 4-1BBL (CD137L) (Source: UniProt; Janeway's Immunobiology). These receptors play a pivotal role in the immunological synapse, where their engagement determines whether a T-cell becomes effector-active or enters a state of anergy or tolerance (Source: Nature Reviews Immunology). In oncology, agonistic monoclonal antibodies like selicrelumab are being developed to trigger these receptors to bolster anti-tumor immunity by enhancing DC-mediated T-cell priming (Source: ClinicalTrials.gov). Conversely, in autoimmune diseases and transplantation, inhibitory agents like the CTLA-4-Ig fusion protein abatacept are used to block these pathways and suppress unwanted immune responses (Source: FDA). Therapeutic targeting of these receptors is a cornerstone of modern immunotherapy, though it requires careful management of potential systemic inflammatory side effects such as cytokine release syndrome (Source: StatPearls).

Other names

DC co-stimulatory moleculesB7 family ligandsCo-stimulatory ligandsAntigen-presenting cell co-stimulatory receptorsSignal 2 receptors

Agonism of co-stimulatory pathways (e.g., CD40) to enhance T-cell activation and anti-tumor immunity, or antagonism/blockade of these pathways (e.g., CD80/CD86) to induce immune tolerance and suppress inflammatory responses.